Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our cash position of $464.1 million at the end of the third quarter provides a solid basis to continue to execute on our programs and priorities till mid-2025 |
| We continue to deliver across our strategic priorities for 2023 by successfully advancing our clinical lead programs both in infectious diseases as well as oncology |
| This clinical progress underscores our strong commitment to introduce new health care solutions to the market |
| But everybody is making, I think, great progress with mRNA vaccines in the flu space, and I am very confident that we have a very competitive and differentiated candidate |
| And from the data that we have seen, we have, I think, a reasonable level of confidence that -- the data from the Phase 2will look strong, including immunogenicity and reactogenicity against A and B strains and that we can move forward to Phase 3 |
| We remain confident in the strength of our IP portfolio and continue to make progress towards the recognition of our pioneering contributions to the development of COVID-19 mRNA vaccines |
| Combined with our highly differentiated capabilities in tumor antigen discovery, the study will be an important basis to further optimize our mRNA backbone to provide differentiated clinical cancer vaccines |
| As another year of strong performance draws to a close, we continue to successfully maintain our forward momentum in the clinical development programs in infectious diseases as well as in oncology, and we are delivering on our strategic priorities |
| So far, we have shared and seen a very, very strong and promising preclinical data, but we have not tested so far our vaccine in the clinical section |
| And we expect to maintain our strong momentum in 2024 with key clinical data readouts from all three studies as well as expected advancement to Phase 3 developments in infectious diseases |
| As Alexander already mentioned, we recently reported solid progress in those programs with the completion of enrollment in the ongoing COVID-19 Phase 2 study and dosing of the first participant in the Phase 2 part of the combined Phase 1/2 study in seasonal flu |
| In B16.F10 tumor bearing mice, the successful induction of solid T cell responses against the superantigen led to a significantly expanded medium survival by approximately 50% for treated mice compared to mice vaccinated with the formulated controlled mRNA |
| We've seen some reformulations by both Pfizer and Moderna, address some of the influenza B streams and improved tolerability |
| And maybe, Ellie, just to add to that, I think what we feel really good about is the breadth of our portfolio, right, with eight rights in Germany and one in the US |
| Together with the progress we have made in safeguarding our investment in innovation and our strong cash position of €464.1 million we will support the execution of our priorities to mid-2025 |
| To finalize our oncology update, the RNA Printer, our highly automated solution for GMP-grade manufacturing of cancer vaccines has achieved its first regulatory milestone |
| Similar to glioblastoma, the B16.F10 melanoma grows very aggressively due to an immune suppressive tumor microenvironment |
| Financial results increased by €0.6 million to a profit of €5.4 million in the third quarter of 2023, an increase by €5.2 million to a profit of €12.7 million for the first nine months of 2023 compared to the same period in 2022 |
| I guess if I heard the question right, your question is how confident are we? And I think we say we are confident |
| We are, therefore, all the more pleased that the immunogenic data obtained on day 21, illustrated on the left side of the slide demonstrates prominent induction of CD8 T cell responses against five and CD3 T cell responses against two of the encoded epitope |
| Our proof-of-concept Phase 1 trial in patients with resected glioblastoma is well on track, as previously mentioned |
| As the pioneering company in mRNA technology, having maintained a traditional scientific leadership for more than two decades, CureVac continues to defend a broad and diversified intellectual property portfolio |
| Second, R&D expenses increased with higher investment in later-stage infectious disease and oncology development programs as well as strengthening the workforce |
| So the glioblastoma trial is actually designed to show this, that the platform works that our cancer vaccine candidate induces strong immunogenicity in users CD8 and CD4 cell responses against the encoded antigens |
| The Printer achieved an initial regulatory milestone by obtaining its first manufacturing license for an mRNA cancer vaccine candidate |
| You can make it for patients convenient and basically, it's better to have the side effects associated with the vaccine, a better to have it in one go with one shot rather than having a twice if it happens by two separate vaccines |
| Third, and still in first nine months of 2022, other income was positively impacted by a one-off amounting to €32.5 million for reimbursement of prepayments and production activity setup at the CMO |
| And there, we also see a significant advantage Unidentified Analyst Thank you, Myriam, Operator Thank you |
| Looking at the validity proceedings on the bottom part of the slide, you can see that on April 6th, 2023, the German Federal Patent Court issued a positive preliminary opinion on the G/C Enrichment Patent supporting its validity |
| However, we do believe, based on our platform, we've seen very good induction of immunicity with relatively low reactogenicity |
| Statement |
|---|
| The decrease over the first nine months year-on-year was primarily driven by lower revenues from our two GSK collaboration agreements |
| Revenue from both collaboration decreased year-on-year and amounted to a total of €28.7 million, the first nine month of 2023 compared to €52.7 million in the same period in 2022 |
| The other thing is that the health systems are really heavily burdened in many, many countries, and especially during the vaccination season again and COVID |
| And maybe I can add to this as well because you're right, the cohort market is going down, but the covert infection per se and the related respiratory disease remains or continues to be a health is, especially for the elderly population |
| So the first one will be regarding the code market, we've seen several of the current players reviewing their potential revenue for the year down based on the current market dynamics |
| Pre-tax losses were €48.7 million for the third quarter and €173.5 million for the first nine months of 2023 |
| Beyond the lower revenues, the operating result was affected by several key drivers |
| First, cost of sales decreased year-on-year, mainly as the impact of our first-generation COVID vaccine subsided |
| Revenues increased by €5.3 million to €16.5 million in the third quarter and decreased by €24.5 million to €31.2 million in the first nine months of 2023 compared to the same period in 2022 |
| I cannot give you a likelihood of success |
Please consider a small donation if you think this website provides you with relevant information